UroGen Pharma Ltd.
URGN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $27,482 | $0 | $20,254 | $24,565 |
| % Growth | – | -100% | -17.5% | – |
| Cost of Goods Sold | $3,278 | $0 | $2,330 | $2,471 |
| Gross Profit | $24,204 | $0 | $17,924 | $22,094 |
| % Margin | 88.1% | – | 88.5% | 89.9% |
| R&D Expenses | $14,008 | $0 | $19,871 | $14,894 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $37,582 | $0 | $34,967 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $34,858 |
| Operating Expenses | $51,590 | $0 | $54,838 | $49,752 |
| Operating Income | -$27,386 | $0 | -$36,914 | -$27,658 |
| % Margin | -99.7% | – | -182.3% | -112.6% |
| Other Income/Exp. Net | -$7,015 | $0 | -$6,537 | -$7,205 |
| Pre-Tax Income | -$34,401 | $0 | -$43,451 | -$34,863 |
| Tax Expense | -$1,054 | $0 | $392 | $2,649 |
| Net Income | -$33,347 | $0 | -$43,843 | -$37,512 |
| % Margin | -121.3% | – | -216.5% | -152.7% |
| EPS | -0.69 | -1.05 | -0.92 | -0.8 |
| % Growth | 34.3% | -14.1% | -15% | – |
| EPS Diluted | -0.69 | -1.05 | -0.92 | -0.8 |
| Weighted Avg Shares Out | 48,057 | 47,740 | 47,422 | 47,031 |
| Weighted Avg Shares Out Dil | 48,057 | 47,740 | 47,422 | 47,031 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,176 | $0 | $2,204 | $2,812 |
| Interest Expense | $7,994 | $0 | $4,068 | $3,892 |
| Depreciation & Amortization | $639 | $0 | $497 | $68 |
| EBITDA | -$25,768 | $0 | -$38,886 | -$26,490 |
| % Margin | -93.8% | – | -192% | -107.8% |